We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $21 · 6 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Design Therapeutics (DSGN) Slides 2.42% as Biotech Stock Tests Key Support - Butterfly Setup - thelegaladvocate.com
Design Therapeutics (DSGN) Slides 2.42% as Biotech Stock Tests Key Support - Butterfly Setup thelegaladvocate.com
Design Therapeutics (DSGN) Dips as Key Support Holds After 2.42% Decline - AAII Bullish - thelegaladvocate.com
Design Therapeutics (DSGN) Dips as Key Support Holds After 2.42% Decline - AAII Bullish thelegaladvocate.com
Design Therapeutics shares jump on encouraging Friedreich ataxia trial results (DSGN) - MSN
Design Therapeutics shares jump on encouraging Friedreich ataxia trial results (DSGN) MSN
DSGN Stock Chart | DESIGN THERAPEUTICS INC (NASDAQ:DSGN) - ChartMill
DSGN Stock Chart | DESIGN THERAPEUTICS INC (NASDAQ:DSGN) ChartMill
Design Therapeutics to present at 2026 Jefferies Global Healthcare Conference on June 4. - Pluang
Design Therapeutics to present at 2026 Jefferies Global Healthcare Conference on June 4. Pluang
Biotech Design Therapeutics to join Jefferies 2026 healthcare fireside chat - Stock Titan
Biotech Design Therapeutics to join Jefferies 2026 healthcare fireside chat Stock Titan
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 04. 28. | After market close (AMC) | $-0.34 | — | — | $0 | — | Scheduled |
| FY2026 Q1 | 2026. 03. 31. | Time TBD | — | $-0.31 | — | — | $0 | Reported |
| FY2025 Q3 | 2025. 09. 30. | Time TBD | — | $-0.64 | — | — | $0 | Reported |
| FY2025 Q2 | 2025. 06. 30. | Time TBD | — | $-0.41 | — | — | $0 | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 05. | Oppenheimer | — | Maintain | Outperform → Outperform | — | Oppenheimer: Outperform |
| 2026. 03. 16. | Jefferies | — | Initiate coverage | — → Buy | — | Jefferies: Buy |
Compare a firm's past rating changes and its actions on other stocks in the same sector.
As of FY2026Q1 · Source: SEC/DART + price data
Filings, earnings, and institutional changes summarized in one paragraph, with source links.
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 5,372,004 | $50.39B | 0.08% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 2,722,754 | $28.97B | 0.05% | — | New position |
See new positions, full exits, and weight changes.